Benzinga | Nov 16, 2021 09:04AM EST

Aegis Capital Maintains Buy on VolitionRX, Lowers Price Target to $9

Aegis Capital analyst Nathan Weinstein maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $10 to $9.